The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Springer Seminars in Immunopathology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF00201905PMID 3330541
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• REGRESSION OF A DISSEMINATED SYNGENEIC SOLID TUMOR

  2003cited by this paper
• The toxicity of recombinant human interleukin-2 in rats following intravenous infusion.

  1987cited by this paper
• Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.

  1986cited by this paper
• A novel approach to the generation and identification of experimental hepatic metastases in a murine model.

  1986cited by this paper
• Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2

  1985cited by this paper
• In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.

  1985cited by this paper
• Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.

  1985cited by this paper
• Immunotherapy of cancer with lymphokine-activated killer cells and recombinant interleukin-2.

  1985cited by this paper
• The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.

  1985cited by this paper
• Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells.

  1985cited by this paper
• Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues.

  1985cited by this paper
• Lymphokine‐activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer

  1985cited by this paper
• Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.

  1985cited by this paper
• Lymphokine-activated killer cells: a new approach to immunotherapy of cancer.

  1985cited by this paper
• Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2

  1984cited by this paper
• Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.

  1984cited by this paper
• Systemic administration of recombinant human interleukin-2 in mice.

  1984cited by this paper
• Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2.

  1984cited by this paper
• Potential for specific cancer therapy with immune T lymphocytes.

  1984cited by this paper
• Adoptive immunotherapy of cancer: accomplishments and prospects.

  1984cited by this paper
• Biological activity of recombinant human interleukin-2 produced in Escherichia coli.

  1984cited by this paper
• The Use of Lymphoid Cells Expanded in IL-2 for the Adoptive Immunotherapy of Murine and Human Tumors

  1984cited by this paper
• Adoptive immunotherapy of cancer: accomplishments and prospects.

  1984cited by this paper
• Structure and expression of a cloned cDNA for human interleukin-2

  1983cited by this paper
• Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells

  1983cited by this paper
• Mechanisms of immunological eradication of a syngeneic guinea pig tumor: participation of a component(s) of recipient origin in the expression of systemic adoptive immunity.

  1983cited by this paper
• The in vitro generation of effector lymphocytes and their employment in tumor immunotherapy.

  1983cited by this paper
• MECHANISMS OF IMMUNOLOGICAL ERADICATION OF A SYNGENEIC GUINEA PIG TUMOR: II. EFFECT OF METHOTREXATE TREATMENT AND T CELL DEPLETION OF THE RECIPIENT ON ADOPTIVE IMMUNITY

  1983cited by this paper
• Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells

  1983cited by this paper
• Adoptive chemoimmunotherapy of a syngeneic murine lymphoma with long-term lymphoid cell lines expanded in T cell growth factor

  1982cited by this paper
• Lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with lectins.

  1982cited by this paper
• Lymphokine-activated killer cell phenomenon. Lysis of natural killer- resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

  1982cited by this paper
• Development of long-term cell lines and lymphoid clones reactive against murine and human tumors: a new approach to the adoptive immunotherapy of cancer.

  1982cited by this paper
• “Anomalous” THY-1(+) killer cells in allogeneic and F1-anti-parental mixed leukocyte culture. Relation to natural killer cells and allospecific cytotoxic T lymphocytes

  1982cited by this paper
• Cell‐mediated suppression of tumor immunity has a non‐specific component. I. Evidence from transplantation tests

  1981cited by this paper
• Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor.

  1981cited by this paper
• T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor

  1980cited by this paper
• In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors.

  1980cited by this paper
• In vivo elimination by specific effector cells of an established syngeneic rat moloney virus-induced sarcoma.

  1979cited by this paper
• Regression and inhibition of sarcoma growth by interference with a radiosensitive T-cell population

  1978cited by this paper
• Regression of established intradermal tumors and lymph node metastases in guinea pigs after systemic transfer of immune lymphoid cells.

  1977cited by this paper
• Passive immunotherapy of cancer in animals and man.

  1977cited by this paper
• Tumor neutralization, immunotherapy, and chemoimmmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro.

  1977cited by this paper
• ADOPTIVE CHEMOIMMUNOTHERAPY OF CANCER IN ANIMALS: A REVIEW OF RESULTS, PRINCIPLES, AND PROBLEMS *

  1976cited by this paper
• Selective in vitro growth of T lymphocytes from normal human bone marrows.

  1976cited by this paper
• MODELS FOR SYNGENEIC ADOPTIVE CHEMOIMMUNOTHERAPY OF MURINE LEUKEMIAS *

  1976cited by this paper
• Inhibition of established transplants of chemically induced sarcomas in syngeneic mice by lymphocytes from immunized donors

  1972cited by this paper
• Accurate identification of experimental pulmonary metastases.

  1966cited by this paper
• TREATMENT OF PRIMARY FIBROSARCOMA IN THE RAT WITH IMMUNE LYMPHOCYTES.

  1964cited by this paper

• Next Generation Natural Killer Cells for Cancer Immunotherapy

  2022cites this paper
• New Developments in T Cell Immunometabolism and Implications for Cancer Immunotherapy

  2022cites this paper
• Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapies

  2021cites this paper
• Therapeutic Vaccination of Hematopoietic Cell Transplantation Recipients Improves Protective CD8 T-Cell Immunotherapy of Cytomegalovirus Infection

  2021cites this paper
• Lymphocyte expansion in bioreactors: upgrading adoptive cell therapy

  2021cites this paper
• Cancer immunotherapy: Breakthrough or “deja vu, all over again”?

  2017cites this paper
• A Perspective of Immunotherapy for Breast Cancer: Lessons Learned and Forward Directions for All Cancers

  2015cites this paper
• An Overview of Treatment for Cervical Cancer with Emphasis on Immune Cell-Based Therapies

  2015cites this paper
• Immune suppression and evasion in patients with head and neck cancer

  2013cites this paper
• Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies.

  2011cites this paper
• Animal Models for Tumor Immunology

  2009cites this paper
• Role of the Immune System in Cancer Development and Therapeutic Implications

  2009cites this paper
• Animal Models for Tumor Immunology

  2009cites this paper
• Animal Models for Tumor Immunology

  2008cites this paper
• Tumours: Immunotherapy

  2007cites this paper
• Lymphokine-activated Killer Cells Mechanism of Cultured Endothelial Injury Induced by Updated Version

  2006cites this paper
• Clinical and Immunological Effects of Recombinant Interleukin 2 Given by Repetitive Weekly Cycles to Patients with Cancer 1

  2006cites this paper
• Cells to Lysis by Interleukin 2-activated Lymphocytes Susceptibility of Chemoresistant Murine and Human Tumor

  2006cites this paper
• Antitumor Activity Human Renal Cell Cancer : Isolation , Characterization , and Interleukin 2 Expanded Tumor-infiltrating Lymphocytes in Updated Version

  2006cites this paper
• Modulation of natural and interleukin-2-induced tumour-cytolytic activities by the members of a protein family related to β-thromboglobulin

  2005cites this paper
• Induktion der nicht-MHC-restringierten T-Zell-Aktivität durch T-Zell-Rezeptor-unabhängige Zytokinstimulation und negative Regulation durch HLA-Klasse-I-Moleküle

  2005cites this paper
• Natural killer and lymphokine-activated killer cell functions in chronic myeloid leukemia

  2005cites this paper
• Antitumour efficacy of lymphokine-activated killer cells loaded with ricin against experimentally induced lung metastases

  2005cites this paper
• Animal Models for Tumor Immunology

  2005cites this paper
• Neue Erkenntnisse der Immunologie bei gynäkologischen Karzinomen

  2005cites this paper
• Immunological Aspects of Neoplasia — The Role of the Thymus

  2004cites this paper
• Use of the subrenal capsule assay to measure antibody-dependent, cell-mediated cytotoxicity against head and neck tumors

  2004cites this paper
• Inmunoterapia activa en el tratamiento de neoplasias hematológicas

  2004cites this paper
• Tumor-derived interleukin-2-dependent lymphocytes in adoptive immunotherapy of lung cancer

  2004cites this paper
• Propagation of cytotoxic effectors from chronic myeloid leukemia patients and cloning of cytotoxic T cells

  2004cites this paper
• Potentiation of the therapeutic index of interleukin-2 immunotherapy by combination with taurine in a syngeneic murine tumour model

  2002cites this paper
• Spontaneous regression of neoplasms: new possibilities for immunotherapy

  2002cites this paper
• Historical Overview of Biologic Response Modifiers

  2000cites this paper
• NK cells modulate MHC class I expression on tumor cells and their susceptibility to lysis.

  2000cites this paper
• Cytokines secreted by lymphokine-activated killer cells induce endogenous nitric oxide synthesis and apoptosis in DLD-1 colon cancer cells.

  2000cites this paper
• Nitric oxide exposure inhibits induction of lymphokine-activated killer cells by inducing precursor apoptosis.

  1998cites this paper
• Autologous bone marrow purging by in situ IL-2 activation of endogenous killer cells

  1997cites this paper
• Kupffer cells and pit cells are not effective in the defense against experimentally induced colon carcinoma metastasis in rat liver

  1996cites this paper
• Cytokines in animal models of cancer

  1996cites this paper
• Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors

  1996influential citation
• The phenotypic changes in tumour infiltrating lymphocytes and tumour cells following intra‐arterial infusion of interleukin‐2 in patients with squamous cell carcinoma

  1995cites this paper
• Immunotherapy for renal cell carcinoma: the era of interleukin-2-based treatment.

  1995cites this paper
• Immunotherapy of Colorectal Cancer

  1994cites this paper
• Effects of Route and Formulation on Clinical Pharmacokinetics of Interleukin-2

  1994cites this paper
• Correlation between ultrastructural and histochemical parameters in lymphokine-activated killer (LAK) cells reacting with target cells in vitro.

  1994cites this paper
• 7-Allyl-8-oxoguanosine (loxoribine) inhibits the metastasis of B16 melanoma cells and has adjuvant activity in mice immunized with a B16 tumor vaccine

  1994cites this paper
• “Spontaneous” regressions of a metastatic adenocarcinoma transmitted by a cadaver kidney graft: Support for immunotherapy?

  1994cites this paper
• Immunotherapy with intralesional and systemic interleukin-2 of patients with non-small-cell lung cancer

  1993cites this paper
• The development and purification of a bispecific antibody for lymphokine-activated killer cell targeting against the rat colon carcinoma CC531

  1993cites this paper
• Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2.

  1992cites this paper
• Immunological effects of alternative weekly interferon-alpha-2b and low dose interleukin-2 in patients with cancer.

  1992cites this paper
• Cancer Immunotherapy: Preclinical Studies with Triazene Compounds

  1992cites this paper
• Strategies for improving antitumor activity utilizing IL-2: Preclinical models and analysis of antitumor activity of lymphocytes from patients receiving IL-2

  1992cites this paper
• The potential role of cytokines in cancer therapy.

  1992cites this paper
• Effects of interferons and other cytokines on tumors in animals: a review.

  1991cites this paper
• IL-2 induces the release of secondary cytokines which stimulate the cytotoxic activity of either NK or CD8+ lymphocytes

  1991cites this paper
• The specificity of lymphokine-activated killer (LAK) cells in vitro: fresh normal murine tissues are resistant to LAK-mediated lysis.

  1991cites this paper
• Immunotherapy for metastatic renal-cell carcinoma

  1991cites this paper
• Control of relapse due to minimal residual disease (MRD) by cell-mediated cytokine-activated immunotherapy in conjunction with bone marrow transplantation.

  1991cites this paper
• Anti-CD3-enhanced interleukin-2 immunotherapy of pulmonary metastases.

  1991cites this paper
• Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity

  1991cites this paper
• Immunotherapy. Neuroblastoma as a model.

  1991cites this paper
• Adoptive Immunotherapy of Advanced Cancer with LAK Cells and Different Dosages of Interleukin-2:Analysis of Lymphocyte Subpopulations

  1990cites this paper
• Culture of human tumor infiltrating lymphocytes in hollow fiber bioreactors.

  1990cites this paper
• Expression of high-affinity IL-4 receptors on murine tumour infiltrating lymphocytes and their up-regulation by IL-2.

  1990cites this paper
• Effect of Cytotoxic Cells on Minimal Residual Leukemia.

  1990cites this paper
• Endogenous substances as drugs. Issues related to the application of cytokines in cancer therapy.

  1990cites this paper
• Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells.

  1990cites this paper
• Interleukin 2 and LAK Cells

  1990cites this paper
• In vivo boosting of lung natural killer and lymphokine‐activated killer cell activity by interleukin‐2: comparison of systemic, intrapleural and inhalation routes

  1990cites this paper
• Down-regulation of LAK cell-mediated cytotoxicity: cancer and ageing.

  1990cites this paper
• Clinical immunotherapy studies in the Surgery Branch of the U.S. National Cancer Institute: brief review.

  1989cites this paper
• Cytotoxic effects on viable human leukemic cells by combinations of lymphokine activated killer cells and monoclonal antibodies.

  1989cites this paper
• Intratumoral LAK cell and interleukin-2 therapy of human gliomas.

  1989cites this paper
• Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation

  1989cites this paper
• Interleukin‐2 enhances biopterins and catecholamines production during adoptive immunotherapy for various cancers

  1989cites this paper
• The nude mouse as a model for the study of human pancreatic cancer.

  1989cites this paper
• Cytokines in cancer therapy.

  1989cites this paper
• In vivo biology of recombinant interleukin-2 infusion in sheep: Cardiopulmonary manifestations of an intravascular immune-inflammatory response

  1989cites this paper
• What's new in urology?

  1989cites this paper
• Monoclonal antibody to a triggering structure expressed on rat natural killer cells and adherent lymphokine-activated killer cells

  1989cites this paper
• Fluctuations of plasma beta 2-microglobulin, soluble interleukin 2 receptor and interferon-gamma concentrations after adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer cells.

  1989cites this paper
• A Correlation between the Expression of CD 8 Antigen and Specific Cytotoxicity of Tumor‐infiltrating Lymphocytes

  1989cites this paper
• Adoptive immunotherapy of urologic tumors.

  1989cites this paper
• Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: effect of pre-therapy nephrectomy.

  1989cites this paper
• The importance of splenectomy for the adoptive immunotherapy of cancer.

  1989cites this paper
• Experience with the Use of High‐Dose Interleukin‐2 in the Treatment of 652 Cancer Patients

  1989cites this paper
• Enhanced in vivo therapy of pulmonary metastases with interferon and interleukin-2.

  1988cites this paper
• Susceptibility of human and murine drug-resistant tumor cells to the lytic activity of rIL2 - activated lymphocytes (LAK)

  1988cites this paper
• This month in investigative urology: adoptive immunotherapy of genitourinary tumors with interleukin-2.

  1988cites this paper
• Anti-tumor reactivity of human lymphokine activated killer (LAK) cells against fresh and cultured preparations of renal cell cancer.

  1988cites this paper
• Lymphokine-activated killer cells in rats. III. A simple method for the purification of large granular lymphocytes and their rapid expansion and conversion into lymphokine-activated killer cells

  1988cites this paper
• The current status and future applications of interleukin 2- and adoptive immunotherapy in cancer treatment.

  1988cites this paper
• Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock.

  1988cites this paper
• Augmentation of cell number and LAK activity in peripheral blood mononuclear cells activated with anti-CD3 and interleukin-2

  1988cites this paper
• A new human pancreatic carcinoma cell line developed for adoptive immunotherapy studies with lymphokine-activated killer cells in nude mice

  1988cites this paper
• Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials.

  1987cites this paper
• Interleukin‐2 activated human killer lymphocytes: Lack of involvement of interferon in the development of IL‐2‐activated killer lymphocytes

  1987cites this paper
• Clinical implications of tumor heterogeneity.

  1987cites this paper
• Development of an automated closed system for generation of human lymphokine-activated killer (LAK) cells for use in adoptive immunotherapy.

  1987cites this paper